Cell surface receptor activation generally leads to changes in mRNA abundance, which may involve regulatory targets in processes working at the post-transcriptional level. Many types of agonists down-regulate vascular smooth muscle angiotensin receptor (AT 1 -R) gene expression, but it is unclear which of these activate post-transcriptional mechanisms. To reconstitute faithfully the normal AT 1 -R mRNA regulatory environment, tetracycline-suppressible promoters drive highly accurate recombinant AT 1 -R mRNA mimics in vascular smooth muscle cells that co-express an endogenous AT 1 -R mRNA. Down-regulation of the latter occurs shortly after stimulating mitogenic receptors or by using forskolin, but only cAMP signaling reduces expression of the recombinant AT 1 -R mRNA. Transcription of the recombinant mRNA is unaffected by cAMP signaling. Deletions of the AT 1 -R mRNA 3-untranslated region do not impair cAMP-mediated down-regulation. Both loss of function and gain of function mutants show the response is mediated by the 5-untranslated region. These observations provide the first direct functional evidence for modulation of vascular AT 1 -R gene expression by a mechanism involving a protein kinase A-regulated post-transcriptional process.
The vasoconstrictive and volume sparing hormone angiotensin II acts through a cell surface G␣ q -coupled AT 1 -receptor (AT 1 -R).
1 A long-standing observation both in vivo and in culture is that AT 1 -R expression is dynamically regulated but by cellular and molecular mechanisms that are not well understood (1, 2) . Since modulation of AT 1 -R mRNA levels is a dominant mechanism for determining target cell hormonal responsiveness (3), understanding how this essential effector of the renin-angiotensin-aldosterone endocrine axis is regulated might provide new insights into how several cardiovascular diseases develop.
Down-regulation of AT 1 -R gene expression occurs within a few hours following activation of vascular smooth muscle cells with many different types of stimuli. These include several growth factors acting through receptor tyrosine kinases (4, 5) , hormones, and autacoids acting through either G␣ s -or G␣ qcoupled receptors (6 -8) , and also direct activators of protein kinase C or the cAMP-dependent protein kinase A (PKA) (6, 8 -10) . We suspect that regulated post-transcriptional mechanisms may account for some or all of the effects of these diverse stimuli. Among the indirect evidence supporting this notion are observations that cAMP-elevating agents do not affect AT 1 -R gene transcription (8, 10) . Although G␣ q -coupled and growth factor receptor signaling suppresses AT 1 -R gene transcription, the more rapid rate of AT 1 -R mRNA decay in response to mitogens relative to transcriptional inhibitors raises the possibility of superimposed post-transcriptional processes (4, 6) . Gaining tight and selective experimental control over AT 1 -R gene transcription would help to clarify these matters.
A role for post-transcriptional regulation in agonist-mediated control of AT 1 -R gene expression has wider implications. Current knowledge about regulated post-transcriptional processes lags considerably the more detailed understanding of how gene transcription rates are modulated by receptor signaling (11) . Although there is a growing appreciation that receptor-operated post-transcriptional control processes likely exist, gathering unambiguous functional evidence for this modality of gene expression regulation is not a trivial matter (reviewed in Ref. 12 ). The typical approach involves measuring how signaling changes mRNA decay rates, using general transcriptional inhibitors like actinomycin D or DRB. The nonspecific effects of these drugs are problematic and raise serious questions about their utility and thus the reliability of many studies that resort to their use. For example, actinomycin D can evoke several stress-like responses in cells, potentially disrupting interfaces between signaling and mRNA metabolism (13) (14) (15) (16) (17) (18) . Furthermore, the mechanism of action of DRB is through inhibiting phosphorylation of RNA polymerase, but its selectivity for the RNA polymerase kinases versus signaling kinases is unknown (19, 20) . Finally, actinomycin D can directly interfere with basal mRNA turnover mechanisms, raising concerns that this might be a more general problem than is currently appreciated (12, 21, 22) .
The present study surmounts these difficulties, providing direct functional evidence that post-transcriptional processes regulated by signaling contribute to modulating vascular AT 1 -R mRNA abundance. We clarify the role of post-transcriptional regulation among the many different factors that can down-regulate AT 1 -R mRNA expression. We begin with the premise that an mRNA will be regulated at the post-transcrip-tional level irrespective of whether it is transcribed from a recombinant or a native locus. Mimicry by a recombinant surrogate of a response affecting its native transcript is essential direct evidence that a post-transcriptional regulatory process exists. The predictive value of recombinant surrogates then rests largely on how accurately mRNA expression dynamics have been reconstructed. By using tetracycline-suppressible transcription factors (23, 24) to express highly accurate AT 1 -R mRNA mimics in vascular smooth muscle cells, we directly test whether post-transcriptional mechanisms are involved in its modulation by specific receptor-coupled signaling systems.
MATERIALS AND METHODS
VSMC Cell Culture-Rat aortic vascular smooth muscle (RASM) cells (passages 8 -25) and A7r5 smooth muscle cells were cultured as described (3, 8) . After reaching confluence, growth media containing 10% serum was replaced with serum-free media for an additional 16 h before initiating treatments.
Retrovirus Production and Infection-Infectious retroviral supernatants were generated by a helper virus-free, transient transfection protocol and used to infect smooth muscle cells with Ͼ99% efficiency as described elsewhere (25) . To ensure stable chromatin integration, cells infected with AT 1 -R mRNA expression viruses were treated with 200 g/ml G418 for 7-10 days. Experiments were then performed on such recombinant cell batches over the succeeding 3-5 passes through subculture, representing studies on cells that have gone through approximately 12-20 population doublings after retroviral infection.
Plasmid Construction-The plasmid pXF42-eGFP was created by removing the neomycin cassette in pXF40-eGFP (10) using BclI and BstBI and first replacing it with a multicloning site using 5ЈGATCAG-GCCTTGTAGGCCTAGGCTCGAGGCCTACAAGGCCTT and its reverse complement (SfiI restriction sites are underlined). The tetracycline transactivator (tTA) cDNA from pUD15-1 (23) was excised with BamHI and EcoRI, blunted, and adapted with the oligonucleotide pair 5ЈAGGCCTAG and 5ЈCTAGGCCTACA before cloning into these SfiI sites. All retroviral AT 1 -R expression plasmids were constructed in pTJM12, a derivative of pTJM9 (25) from which the internal CMV promoter was removed using BamHI and HindIII before blunting and self-ligation. To create pTSO33, which is the wild-type AT 1 -R mRNA expression vector, eight copies of the tetracycline operator sequence (tetOp) derived from pUD10-3 (23) as a XhoI-StuI fragment were fused upstream of a PstI-KpnI fragment containing the minimal (Ϫ54 to ϩ104 base pair) rat AT 1a -R gene promoter (26) . A KpnI-DraIII fragment was fused downstream of this, derived from the vector pTSO31 (3), providing rat vascular AT 1 -R cDNA sequence (27) between base pairs 104 and 849, wherein a hemagglutinin (HA) epitope was inserted at the fourth amino acid of the receptor open reading frame. A 1.8-kb DraIII-StuI fragment derived from a subclone of the rat AT 1 -R genomic clone RGL8 was cloned downstream from this (26) . This latter fragment encodes the remainder of the third exon of the rat AT 1 -R gene, including its open reading frame and 3Ј-UTR region and ϳ370 base pairs of additional non-transcribed genomic sequence that encode downstream polyadenylation signals. The vector pTSO41 uses the tetracycline-regulated minimal CMV promoter, as a XhoI-EcoRI fragment from pUD10-3, instead of the minimal AT 1 -R promoter, but is otherwise identical to pTSO33 downstream from this. The vector pTSO31 is the same as pTSO41 at the 5Ј end but uses an SV40 pAϩ signal, rather than AT 1 -R pAϩ signals as transcriptional terminators (3) . Plasmids for the various mutant and deletion AT 1 -R mRNA were constructed using shuttle vectors and standard oligonucleotide site-directed mutagenesis or polymerase chain reaction protocols. The plasmid pXF40-eGFP (10) served as a base to construct chimera AT 1 -R/eGFP mRNAs, and unlike the AT 1 -R mRNA constructs, these were infected into cells that express the tTA through infection with the retrovirus pTSO5 (3). All mutations and polymerase chain reaction-generated fragments were verified by sequencing using the Emory University DNA sequencing core facility before subcloning into the retroviral expression vectors. Plasmids and their complete sequences are available on request.
Ribonuclease Protection Assays and Data Analysis-Samples of total RNA were hybridized with a mixture of gel-purified, [␣- 32 P]UTP-labeled antisense AT 1 -R and cyclophilin (Cyp) riboprobes and treated with RNase A and T1 before resolution on sequencing gels as described in detail elsewhere (3). All AT 1 -R riboprobes incorporate sequences antisense to the HA epitope. The hybridization signals were quantified from phosphorimages using a volume integration protocol in the ImageQuaNT software. AT 1 -R mRNA hybridization signals were divided by those for Cyp in each sample, and the data are normalized to this ratio in untreated control samples, which is taken as 100%. Decay rate constants were calculated after combining all sets of experimental data for a given mRNA construct and protocol and performing an iterative best-fit computation using the single-site exponential decay function in GraphPad Prism.
Nuclear Run-on Assays-Nuclei from confluent RASM cells were isolated, and in vitro run-on transcription assays using 250 Ci of [ 32 P]UTP (3000 Ci/mmol) were conducted in a 200-l volume as described previously (8) . Radiolabeled nuclear RNA was isolated and split into 2 equivalent aliquots and each hybridized in solution at 22°C precisely as described (28) , using either 0.21 nmol of biotinylated antisense HA epitope oligonucleotide (5Јbiotin-(18 carbon spacer)-AACG-GCGTAGTCTGGGACGTCGTATGGGTAC) or 0.21 nmol of oligonucleotide antisense to the L32 ribosomal protein mRNA (5Јbiotin-(18 carbon spacer)-TTCACATATCGGTCCGACTGGTGCCTGATGA) as an internal control. After an overnight hybridization, streptavidin-coated ferrous beads (Promega, Inc. Madison, WI; 300 g, ϳ1.25 nmol capacity) were added. After a brief incubation, the samples were clamped against a magnetic bar and washed six times with 1-ml aliquots of RNase-free 0.1ϫ SSC. The samples were eluted in a sequencing gel loading dye by heating to 90°C for 10 min before resolution by electrophoresis through 5% polyacrylamide sequencing gels.
RESULTS
Expression of recombinant AT 1 -R mRNAs in vascular smooth muscle cells from tetracycline-regulated promoters exploits a helper virus-free, non-replicating retroviral vector system (Fig. 1) . The gene transfer efficiency is routinely close to 100% using this, allowing for rapid derivation of new recombinant cell populations compared with alternative methods. Stable chromatin integration of the recombinant genes allows for continued study on successive passages of cells following a single infection protocol. Fluorescence-activated cell sorting (10) was used first to create vascular smooth muscle cell lines enriched for expression of the tetracycline transactivator (23) using the self-regulating vector pXF42-eGFP (Fig. 1a) . After expansion and storage, these cells were used to provide a uniform genetic background for subsequent transduction with recombinant AT 1 -R retroviruses.
The vector used to express what is termed the wild-type recombinant AT 1 -R mRNA (referred herein as wtAT 1 -R), which represents the most accurate possible mimic of the native transcript, is shown in Fig. 1b . This anhydrotetracycline (Antet)-suppressible mRNA begins and ends, respectively, with transcriptional initiation (minimal promoter) and termination (polyadenylation) sequences derived from the native AT 1 -R gene (26) . In using these elements, rather than heterologous promoter and poly(A) ϩ sequences, the composition of the 5Ј and 3Ј ends of the recombinant mRNA precisely mimic those of the major native 2.2-kb AT 1 -R transcript expressed in VSMC and other cells (27) . An in-frame hemagglutinin (HA) epitope within the amino terminus of the AT 1 -R open reading frame is the only difference between the recombinant wtAT 1 -R and the native transcript, which was necessary to distinguish between them using ribonuclease protection assays.
A7r5 smooth muscle do not to express the AT 1 -R gene natively (3), but after sequential infection with tTA and wtAT 1 -R mRNA viruses, they display an anhydrotetracycline (Antet)-suppressible 2.2-kb AT 1 -R mRNA (labeled "tetOp"). It migrates on agarose gels the same as the more abundant native transcript in a second line of cells termed RASM (Fig. 1c) , demonstrating that the expression vector produces the expected AT 1 -R mRNA product. Notably, this is slightly smaller than the 2.4-kb transcript produced from the vector TSO31 (see below), which has additional heterologous 5Ј-and 3Ј-UTR sequences derived from CMV and SV40 elements (3). The recombinant wtAT 1 -R mRNA presumably migrates at 2.2 kb in recombinant RASM cells, inferred from the finding that none of the detectable hybridization signals are suppressed by Antet treatment. Of note, the weaker 3.2-kb transcript observed in RASM mRNA represents a previously cloned alternately spliced product of the native AT 1 -R gene, rather than a recombinant molecule (26, 27) . The barely detectable hybridization signals migrating at ϳ6 kb, labeled "LTR," likely represent the transcript driven by the LTR promoter, essentially reflecting a neomycin mRNA with antisense AT 1 -R mRNA sequences in the 3Ј-untranslated region (Fig. 1b) .
Our ribonuclease protection assay discriminates recombinant from native transcripts in a single sample, because the riboprobes used incorporate sequence antisense to the HA epitope in addition to the flanking AT 1 -R mRNA sequence (Fig.  2) . The phosphorimage (Fig. 2a) shows a single large protected fragment representative of the recombinant wtAT 1 -R mRNA. The three smaller fragments reflect the native mRNA because synthesis of the riboprobe from a recombinant template crosses over both the heterologous HA epitope and an exon that is alternatively spliced within the native mRNA 5Ј-UTR (26, 27) . Although the recombinant transcript is suppressed after treatment with 1 g/ml Antet, this does not affect expression of the native AT 1 -R mRNA, showing the selectivity of Antet (Fig. 2b) . A comparatively delayed decay occurs for the wtAT 1 -R in cells treated with actinomycin D (20 g/ml) relative to the effect of Antet, indicating that actinomycin D strongly interferes with basal AT 1 -R decay processes.
Previous studies have established that forskolin, a direct activator of adenylyl cyclase, down-regulates the AT 1 -R mRNA through activation of PKA, because this response is inhibited in cells expressing a highly selective polypeptide inhibitor of the cAMP-dependent kinase (10) . A bolus (5 or 10 M) of forskolin was used to stimulate PKA in RASM cells, and recombinant wtAT 1 -R mRNA levels were measured at various times thereafter (Fig. 3) . Treatment with forskolin causes down-regulation of the mRNA, with an apparent half-life of 1.7 h (Table I) . Notably, decay rates following Antet treatment or Antet plus forskolin treatment are similar (Table I) .
Because Antet suppresses transcription by a mechanism that relieves transactivation, rather than through direct inhibition (23), nuclear run-on assays were performed to ensure that forskolin does not directly inhibit transcription of the wtAT 1 -R gene. Nuclei were collected after treating cells for 45 min with forskolin, reasoning that any transcriptional suppression caused by forskolin by this point should be quite pronounced to account for its affect on steady-state mRNA levels. For comparison, cells were also treated with Antet to assess transcriptional suppression and with Antet plus forskolin to test whether forskolin interferes with the mechanism of action for Antet. The recombinant AT 1 -R transcripts were selectively captured by solution hybridization using a biotinylated antisense oligonucleotide directed against its HA epitope (28). Capture of the ribosomal L32 protein mRNA similarly from aliquots of the same samples served as an internal control. Antet treatment for 45 min suppresses the transcripts captured by the wtAT 1 -R probe, with transcription to about 10% of control levels consistent with the "leak" that occurs in this system (3) (Fig. 4) . Similar results were obtained in other run-on experiments in which the Antet treatment period was 30 min, suggesting Antet-mediated transcriptional suppression occurs rapidly (data not shown). Co-treatment with forskolin and Antet does not interfere with the transcriptional suppression, and forskolin has no effect on transcription compared with vehicletreated cells. These observations establish that transcriptional suppression cannot account for the forskolin-mediated reduction of the recombinant wtAT 1 -R mRNA. To determine if mitogenic receptor signaling affects recombinant wtAT 1 -R mRNA expression, the cells were stimulated for up to 6 h following a bolus of either angiotensin II or the growth factor PDGF-BB. As shown in Fig. 5a , their effects are not comparable to that of forskolin, wherein angiotensin II has no effect and PDGF reduces the recombinant mRNA only at the latest time point tested. Whereas the recombinant mRNA is largely unaffected by mitogens, the native AT 1 -R mRNA is down-regulated in the same samples, which establishes that the agonists nevertheless evoked their regulatory effects on AT 1 -R gene expression (Fig. 5a) . The modest suppressive effect of PDGF on the recombinant wtAT 1 -R mRNA at the latter time point might be due to a transcriptional effect. To test this, the PDGF response was measured in cells expressing a recombinant mRNA from the vector TSO41, which is identical to the wtAT 1 -R mRNA except that it is driven from a tetracyclinesuppressible minimal CMV promoter. This renders an mRNA with ϳ60 additional bases of heterologous CMV sequence in the 5Ј-UTR. As shown in Fig. 5b , the TSO41-derived recombinant AT 1 -R mRNA is down-regulated by forskolin but unaffected by PDGF-BB treatment. We conclude that the reduction of the recombinant wtAT 1 -R mRNA in response to PDGF-BB is most likely due to a modest degree of transcriptional suppression at the minimal AT 1 -R promoter.
To test whether the AT 1 -R mRNA is regulated in another smooth muscle cell phenotype, levels of the recombinant wtAT 1 -R mRNA levels were measured after infection of A7r5 cells with the display system. Like RASM, A7r5 cells are derived from rat thoracic aorta (29) but differ in morphological and growth characteristics (30) . 2 As shown in Fig. 6 , 8-h treatments with either Antet or forskolin reduce wtAT 1 -R mRNA expression in each cell line. In contrast, angiotensin II has no effect in either cell line, and PDGF-BB treatment only reduces the mRNA when expressed in RASM cells. Thus, both cell lines appear to support PKA-specific down-regulation.
We compared four possible combinations of minimal AT 1 -R or minimal CMV promoters and AT 1 -R or SV40 polyadenylation signals to determine if heterologous sequences influence forskolin responsiveness or intrinsic decay rates. These nominally full-length mRNAs (wtAT 1 -R, KX38, TSO41, and TSO31) show generally equivalent Antet-mediated decay rates, although forskolin-stimulated down-regulation of the TSO31 mRNA is slightly delayed compared with the others (Fig. 7 ; see also Table I ). Most significantly, each is down-regulated by forskolin treatment, and like the wtAT 1 -R mRNA, these each respond to co-treatment with forskolin and Antet without an accelerated decay compared with Antet alone. Because a combination of minimal AT 1 -R gene promoter and SV40 poly(A) ϩ signals (KX38) share response characteristics with the wtAT 1 -R mRNA, a series of 3Ј-UTR deletion mutants were expressed using SV40 poly(A) ϩ signals for termination. As seen in Fig. 7 , these mutants show a tendency for increasingly slower rates of decay as a function of deletion, following Antet treatment. This suggests elements within the 3Ј-UTR confer basal decay characteristics. Again most notably, forskolin treatment alone causes down-regulation of each construct, indicating the 3Ј-UTR does not mediate this response to PKA activation. Furthermore, co-treatment with forskolin and Antet does not lead to an accelerated rate of decay for any of these 
TABLE I Kinetic analysis of recombinant AT 1 -R mRNA decay
The decay rate constants (k) and their S.E. are derived from non-linear analysis of data from combined experiments using a single-site exponential decay function. Half-lives (t 1/2 ) were calculated from the relationship t 1/2 ϭ 0.693/k. ND, not determined. STABLE represents no response to forskolin treatment. eight mRNAs compared with the effect of Antet alone. These results indicate that the 3Ј-UTR does not mediate PKA-stimulated down-regulation (Table I) . We next tested if the 271-base long AT 1 -R mRNA 5Ј-UTR determines responsiveness to PKA signaling. Deletion of the 5Ј-UTR from the wtAT 1 -R mRNA background making KX30 completely impairs forskolin-stimulated down-regulation, and the down-regulation by Antet shows this is not attributable to intrinsic stabilization of the mRNA (Fig. 8, see also Table I ). Furthermore, forskolin clearly evoked the regulatory process in these cells as shown by down-regulation of the internal control native mRNA in the same samples (Fig. 8) . Because this mRNA does not have any predictable 5Ј-UTR sequence, we also deleted it within the context of the KX38 mRNA background to make KX63. This would have an ϳ60-base heterologous 5Ј-UTR remnant derived from the CMV minimal promoter region. The KX63 mRNA is also insensitive to forskolin yet is not intrinsically stabilized (Fig. 9 , see also Table I) ). To control for length effect, the 5Ј-UTR was inverted to make KX65, and this is also shown to be insensitive to forskolin signaling but also not intrinsically stabilized (Fig. 9) .
We next asked if the 5Ј-UTR region could confer PKA-mediated regulatory characteristics upon a heterologous mRNA. It was next cloned upstream of an eGFP coding region in either the forward (KX41) or reverse (KX41(Ϫ)) orientations and compared with a control eGFP mRNA (XF40). The XF40 mRNA is unaffected by forskolin treatment but decays with a half-life of ϳ5.4 h after Antet treatment, representing the most stable mRNA used in this study ( Fig. 9 ; see also Table I ). Forskolin treatment causes down-regulation of the forward orientation 5Ј-UTR AT 1 -R/eGFP mRNA chimera but not that with a reverse orientation 5Ј-UTR. Intriguingly, the forward 5Ј-UTR chimera but not the reverse also acquires the more rapid basal decay kinetics associated with AT 1 -R mRNA, which we suspect may be attributable to basal levels of PKA activity. Together, these observations indicate that the 5Ј-UTR region functions as a cis-acting element that directs post-transcriptional downregulation of AT 1 -R mRNA expression in response to PKA activation.
DISCUSSION
Difficulties in deriving direct and unambiguous evidence that specific mRNAs are susceptible to regulated post-transcriptional control has impeded progress in developing an understanding of this potentially important interface between signaling and gene expression. A careful reconstitution of the normal cellular environment for an mRNA ensures that a suspected regulatory circuitry remains intact and provides a stringent approach to test this concept. Current "circular" models of mRNA structure argue that the 5Ј and 3Ј ends of an mRNA are co-engaged in a complex of interacting proteins linking the 5Ј-cap structure with the 3Ј poly(A) ϩ tail (reviewed in Ref. 31 ). Reasoning that post-transcriptional regulation of the AT 1 -R mRNA might very well depend upon accurate formation or function of these or other context-specific complexes, which may also be cell type-specific, we were cautious to recreate a recombinant mRNA as precisely as possible. Coupled with the comparatively selective tetracycline-regulated system, as opposed to general transcriptional inhibitors, and expressing these recombinants in their native cell system, the most accurate possible reconstitution of the normal AT 1 -R mRNA regulatory environment has been achieved. From the behavior of the recombinant mRNAs in such a system, solid inferences can be drawn about how the native AT 1 -R mRNA is regulated.
A primary goal of this study was to establish a direct functional test for whether post-transcriptional regulation contributes to vascular smooth muscle AT 1 -R mRNA down-regulation. Finding this, a secondary goal was to ascertain which of the receptor signaling systems that down-regulate AT 1 -R gene expression do so through control by post-transcriptional mechanisms. Three lines of evidence developed in this study indicate a PKA-regulated post-transcriptional process targets the vascular AT1-R mRNA. First, the experimental design is predicated on recapitulating a reduction in steady-state expression of the recombinant wtAT 1 -R mRNA should a stimulus evoke a post-transcriptional regulatory process. We show this not only for the stringently designed wtAT 1 -R mRNA but also with great consistency on seven additional independent recombinant AT 1 -R transcripts (see Fig. 7 ). The second line of evidence is that nuclear run-on analysis shows that the cAMP-mediated effect is not attributable to interference with tTA-mediated transactivation of the recombinant gene. We found this important to evaluate because of the formal possibility that cAMP signaling might unexpectedly inhibit the tTA protein or its mechanism of action. Third, both loss of function and gain of function mutants establish that the 5Ј-UTR is an obligate component of PKA-mediated AT 1 -R mRNA down-regulation. Acquired from analysis of five independent recombinant mRNAs, they argue quite strongly that the response to PKA signaling is an intrinsic feature of the mRNA molecule. Taken together, these observations provide the first direct and largely unam- This study significantly extends previous findings that predicted post-transcriptional control by PKA signaling and clarifies the mechanism of AT 1 -R mRNA down-regulation caused by mitogenic signaling (4, 6, 7, 10) . The post-transcriptional response has features of inherent specificity, in that recombinant mRNA down-regulation occurs following cAMP but not mitogenic signaling. This is consistent with previous nuclear run-on observations, wherein AT 1 -R gene transcription is suppressed some 50 -80% by mitogenic signaling, but has never been observed in response to cAMP signaling (4, 6, 8) . We infer from this that mitogens likely down-regulate the endogenous transcript predominantly, if not entirely, by a mechanism that involves transcriptional suppression rather than post-transcriptional control. The present direct, function-based approach and the acquisition of reliable AT 1 -R mRNA half-life estimates made possible by using the tetracycline-regulated system highlights previous uncertainties that have plagued us regarding mechanisms of mitogen-induced down-regulation. Despite the evidence showing mitogen-induced transcriptional suppression, the more rapid rate of AT 1 -R mRNA down-regulation caused by mitogens compared with actinomycin D or DRB treatment raised the possibility of post-transcriptional regulation because the mRNA did not seem capable of decaying fast enough. We now show just how inaccurate the toxin chasebased half-life estimates were. By using Antet instead, a Ͻ2-h half-life shows that a significant reduction in steady-state mRNA can follow inhibiting AT 1 -R gene transcription, even if only partially. Additionally, the failure of angiotensin II treatment to reduce levels of the recombinant wtAT 1 -R mRNA raises qestions about the relevance of previously described angiotensin II-stimulated AT 1 -R mRNA binding protein activity (7). They now seem unlikely to reflect factors involved in post-transcriptional regulation.
We are cautious not to describe this post-transcriptional response as PKA-regulated AT 1 -R mRNA "destabilization." Of the several mRNAs created for this study, none are reduced at a faster rate by combined treatment with forskolin and Antet, compared with transcriptional suppression alone. Destabilization or "regulation of mRNA stability" implies a different kinetic behavior than this. As the evidence shows that a regulated post-transcriptional mechanism must account for downregulation of the mRNA caused by forskolin, we speculate either of two general mechanisms could explain the behavior of the AT 1 -R mRNA. One possibility is that PKA stimulates AT 1 -R mRNA degradation but through a mechanism that functions upstream of the mRNA decay processes. For example, PKA may prematurely "uncouple" pre-existing mRNA from its normal state and shuttle it into a degradation process wherein decay per se is rate-limiting. Thus, mRNAs would show equivalent decay kinetics irrespective of whether they enter the degradation process through a default or PKA-regulated process.
A more attractive possibility is that separate pools of the AT 1 -R mRNA exhibit differential sensitivity to PKA signaling. By the following logic, our data might be more consistent with this latter speculation. At steady state, the rates of transcript formation and degradation must be equivalent. The similarity between Antet and forskolin-stimulated decay rates are consistent with a common failure to regenerate the cellular pool. The pool is not refilled following Antet obviously because transcription is suppressed. Because we show that forskolin does FIG. 9. 5-UTR orientation dependence and conference of responsiveness to a more stable mRNA. Upper panels, AT 1 -R mRNAs in which the 5Ј-UTR is deleted (KX63) or inverted (KX65) are refractory to forskolin (5 M) treatment compared with their control (TSO41), yet all have essentially similar Antet decay characteristics. Because the reverse 5Ј-UTR orientation in the wtAT 1 -R mRNA background did not express a detectable mRNA, the TSO41 background with its minimal CMV promoter was used instead. Lower panels, Antet-and forskolin-initiated decay kinetics for a control eGFP mRNA (XF40) and chimeras bearing the AT 1 -R 5Ј-UTR in either the forward (KX41) or reverse (KX41(Ϫ)) orientations. Each point represents data from two to four experiments. not affect transcription, we speculate that PKA might activate a process that selectively targets only newly transcribed AT 1 -R mRNA molecules. This would have the kinetic appearance of failing to regenerate the cellular pool much like for Antet but through a distinct mechanism. A period might exist in which the mRNA is susceptible to this PKA-regulated process. At latter points in its maturation pathway, it either acquires a defense against it or is no longer associated with the components that PKA presumably regulates. Testing this notion will involve developing schemes that selectively measure nascent mRNAs and distinguish them from more mature mRNAs.
The trans-acting iron-responsive element mRNA-binding proteins connect both iron availability and intracellular oxide concentrations to the stability and translation of specific mRNAs by interacting with specific mRNA cis-acting elements (21, (32) (33) (34) . To the extent that oxidative metabolites serve as second messengers (35) , the iron response element-binding proteins remain one of the few unambiguous interfaces between mRNA stability regulation and signal transduction or changes in the extracellular environment.
Other models systems for the concept that the more traditional receptor-regulated signaling pathways control post-transcriptional processes are not without ambiguity. Interestingly, several of these describe cAMP-regulated processes, including down-regulation of adrenergic receptor mRNAs (36 -39) and a plasminogen activator inhibitor mRNA (40, 41) and up-regulation of a lactate dehydrogenase mRNA (42, 43) . Concomitant transcriptional regulation by the stimuli that affect steadystate levels of these mRNA and the various toxin-based pulse-mRNA chase paradigms used in these studies are the basis for most uncertainty regarding the role of post-transcriptional processes. Nevertheless, they have compelling biochemical findings that largely correlate mRNA protein binding activity and mRNA structure relationships with responses to stimuli. Curiously, they all implicate 3Ј-UTR adenylate/uridylate (AU)-rich domains as signaling responsive mRNA elements. On this basis, they seem to differ fundamentally from those likely affecting the AT 1 -R mRNA, because its 5Ј-UTR is devoid of AU-rich elements. Also, because AU-rich elements function as powerful epitopes driving the intrinsic decay of many highly unstable mRNAs (44) , it remains unclear how they might function as conditional stability determinants responsive to cAMP signaling or other pathways (45, 46) . In summary, this study has general importance by showing a stringent approach useful for understanding roles of posttranscriptional processes in regulation of mRNA abundance. More specifically, it clarifies the general mechanisms that are involved in agonist-induced down-regulation of vascular smooth muscle AT 1 -R gene expression. Future studies will be directed at achieving improved insight into the factors that mediate this process. We also hope to gain some insight into how it contributes to the well known plasticity of smooth muscle cell gene expression and its relevance to the generally suppressive role of PKA in smooth muscle cell proliferation and migration (47) .
